Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
Clinical and Molecular Hepatology
;
: 168-176, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-119487
ABSTRACT
BACKGROUND/AIMS:
Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV.METHODS:
In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study.RESULTS:
Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2 points, and the overall end-stage liver disease score decreased from 16+/-5 to 14+/-10 (mean +/- SD, P or =2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).CONCLUSIONS:
Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Índice de Severidad de la Enfermedad
/
ADN Viral
/
Adenina
/
Oportunidad Relativa
/
Virus de la Hepatitis B
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Estudios de Cohortes
/
Lamivudine
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio observacional
/
Factores de riesgo
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Clinical and Molecular Hepatology
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS